R1 RCM - RCM Stock Forecast, Price & News

R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. The company was founded in 2003 and is headquartered in Murray, Utah.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on RCM shares. TheStreet upgraded R1 RCM from a "d" rating to a "c" rating in a research note on Monday, May 9th. Barclays reaffirmed an "overweight" rating and issued a $29.00 price target on shares of R1 RCM in a report on Wednesday, June 29th. JPMorgan Chase & Co. initiated coverage on R1 RCM in a report on Monday, August 1st. They issued an "overweight" rating for the company. Finally, Deutsche Bank Aktiengesellschaft increased their target price on R1 RCM from $26.00 to $31.00 in a report on Thursday, August 4th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, R1 RCM presently has an average rating of "Moderate Buy" and a consensus price target of $30.17.

R1 RCM Price Performance

NASDAQ:RCM opened at $25.02 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.57. The stock's 50-day simple moving average is $23.10 and its 200 day simple moving average is $23.92. The company has a market cap of $10.41 billion, a P/E ratio of 139.01, a P/E/G ratio of 5.91 and a beta of 0.91. R1 RCM has a 52-week low of $18.71 and a 52-week high of $27.86.

Insider Buying and Selling

In related news, CEO Joseph Gerard Flanagan sold 200,000 shares of R1 RCM stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $24.98, for a total transaction of $4,996,000.00. Following the completion of the transaction, the chief executive officer now owns 2,792,221 shares in the company, valued at $69,749,680.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider John M. Sparby sold 4,365 shares of the business's stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $26.03, for a total value of $113,620.95. Following the completion of the sale, the insider now directly owns 163,772 shares in the company, valued at $4,262,985.16. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Joseph Gerard Flanagan sold 200,000 shares of the business's stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $24.98, for a total value of $4,996,000.00. Following the completion of the sale, the chief executive officer now owns 2,792,221 shares of the company's stock, valued at $69,749,680.58. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 409,056 shares of company stock worth $10,266,789. Company insiders own 59.40% of the company's stock.